Kissei Pharmaceutical Co., Ltd. is a Japanese research-driven biopharmaceutical company established in 1946 and headquartered in Matsumoto, Nagano Prefecture. Originally founded to produce generic pharmaceuticals, the company has evolved into a fully integrated pharmaceutical firm focused on the discovery, development, manufacturing and marketing of prescription drugs and medical devices. Kissei Pharmaceuticals operates with a mission to address unmet medical needs through innovative therapies in key therapeutic areas.
The company’s core business activities center on ethical pharmaceuticals, with a particular emphasis on nephrology, infectious diseases, metabolic disorders and central nervous system conditions. Kissei maintains in-house capabilities for small-molecule synthesis, biologics research and formulation development. Commercial operations include a domestic sales force in Japan as well as partnerships and licensing agreements that facilitate product registration and distribution in North America, Europe and other Asian markets.
Among Kissei’s notable products is peramivir (marketed under the trade name Rapiacta), an intravenous neuraminidase inhibitor for the treatment of influenza. The company also markets cardiovascular agents such as azosemide, an oral diuretic, and imidapril, an ACE inhibitor for hypertension. In addition to its marketed portfolio, Kissei advances a pipeline of clinical-stage assets targeting chronic kidney disease, diabetic complications and novel immuno-oncology candidates, leveraging collaborations with academic institutions and global partners.
Under the leadership of President and Representative Director Yoshihiro Yamada, Kissei Pharmaceutical has strengthened its research alliances and expanded its manufacturing footprint. The company’s operations encompass state-of-the-art facilities in Matsumoto for active pharmaceutical ingredient production and drug formulation. By combining traditional Japanese quality standards with a global outlook, Kissei continues to pursue strategic growth opportunities and deliver value to patients and stakeholders worldwide.
AI Generated. May Contain Errors.
Free KSPHF Stock Alerts